Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
21 Setembro 2023 - 8:00AM
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the
“Company”), a clinical-stage biopharmaceutical company focused on
rare diseases, today announced that Dr. Denise Scots-Knight, Chief
Executive Officer, will participate in a Fireside Chat at the 2023
Cantor Global Healthcare Conference on Wednesday, September 27,
2023 at 10:55am ET / 03:55pm BST.
A live audio webcast of the presentation can be
accessed through the Investors section of the Company’s website at
www.mereobiopharma.com/investors. An archived replay of the
webcast will be available on the Company’s website for two weeks
following the live event.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company
focused on the development of innovative therapeutics for rare
diseases. The Company has two rare disease product candidates,
setrusumab for the treatment of osteogenesis imperfecta (OI) and
alvelestat primarily for the treatment of severe
alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD).
The Company’s partner, Ultragenyx Pharmaceutical, Inc., has
initiated a pivotal Phase 2/3 pediatric study in young adults (5 to
<26 years old) for setrusumab in OI and a Phase 3 study in
pediatric patients (2 to <7 years old) in the first half of
2023. The partnership with Ultragenyx includes potential milestone
payments of up to $245 million (following the recent $9 million
milestone) and royalties to Mereo on commercial sales in Ultragenyx
territories. Mereo has retained EU and UK commercial rights and
will pay Ultragenyx royalties on commercial sales in those
territories. Setrusumab has received orphan designation for
osteogenesis imperfecta from the EMA and FDA, PRIME designation
from the EMA and has pediatric disease designation from the FDA.
Alvelestat has received U.S. Orphan Drug Designation for the
treatment of AATD, Fast Track designation from the FDA, and
positive data were reported from a Phase 2 proof-of-concept study
in North America, Europe and the UK. In addition to the rare
disease programs, Mereo has two oncology product candidates in
clinical development. Etigilimab (anti-TIGIT) has completed a Phase
1b/2 basket study evaluating its safety and efficacy in combination
with an anti-PD-1 in a range of tumor types including three rare
tumors and three gynecological carcinomas - cervical, ovarian, and
endometrial and is an ongoing Phase 1b/2 investigator led study at
the MD Anderson Cancer Center in clear cell ovarian cancer;
Navicixizumab, for the treatment of late line ovarian cancer, has
completed a Phase 1 study and has been partnered with OncXerna
Therapeutics, Inc. in a global licensing agreement that includes
payments of up to $300 million in milestones and royalties.
Forward-Looking Statements
This press release contains “forward-looking
statements,” including the Company’s expectations regarding a study
in pediatric patients evaluating setrusumab, and the Company’s
pipeline of product candidates. All statements other than
statements of historical fact contained in this press release are
forward-looking statements within the meaning of Section 27A of the
U.S Securities Act of 1933, as amended, and Section 21E of the U.S
Securities Exchange Act of 1934, as amended. Forward-looking
statements usually relate to future events and anticipated
revenues, earnings, cash flows or other aspects of our operations
or operating results. Forward-looking statements are often
identified by the words “believe,” “expect,” “anticipate,” “plan,”
“intend,” “foresee,” “should,” “would,” “could,” “may,” “estimate,”
“outlook” and similar expressions, including the negative thereof.
The absence of these words, however, does not mean that the
statements are not forward-looking. These forward-looking
statements are based on the Company’s current expectations, beliefs
and assumptions concerning future developments and business
conditions and their potential effect on the Company. While
management believes that these forward-looking statements are
reasonable as and when made, there can be no assurance that future
developments affecting the Company will be those that it
anticipates. All of the Company’s forward-looking statements
involve known and unknown risks and uncertainties some of which are
significant or beyond its control and assumptions that could cause
actual results to differ materially from the Company’s historical
experience and its present expectations or projections. Such risks
and uncertainties include, among others, the uncertainties inherent
in the clinical development process; the Company’s reliance on
third parties to conduct and provide funding for its clinical
trials; the Company’s dependence on enrolment of patients in its
clinical trials; and the Company’s dependence on its key
executives. You should carefully consider the foregoing factors and
the other risks and uncertainties that affect the Company’s
business, including those described in the “Risk Factors” section
of its latest Annual Report on Form 20-F, reports on Form 6-K and
other documents furnished or filed from time to time by the Company
with the Securities and Exchange Commission. The Company wishes to
caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date hereof. The Company
undertakes no obligation to publicly update or revise any of our
forward-looking statements after the date they are made, whether as
a result of new information, future events or otherwise, except to
the extent required by law.
Mereo BioPharma Contacts: |
|
|
|
Mereo |
+44 (0)333 023 7300 |
Denise Scots-Knight, Chief Executive Officer |
|
Christine Fox, Chief Financial Officer |
|
|
|
Burns McClellan (Investor Relations Adviser to
Mereo) |
+01 646 930 4406 |
Lee Roth |
|
|
|
Investors |
investors@mereobiopharma.com |
Mereo BioPharma (NASDAQ:MREO)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Mereo BioPharma (NASDAQ:MREO)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025